<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-145759</identifier>
<setSpec>0211-6995</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">De novo hemolytic uremic síndrome in a kidney-pandreas recipient in the postoperative period</dc:title>
<dc:description xml:lang="en">Among the numeruos adverse side effects of tacrolimus (TAC), de novo thrombotic microangiopathy stands out as an infrecuente but severe complication. Renal dysfunction is the only alteration that should lead to suspicion of thrombotic microangiopathy, because the clinical features of intravascular hemolysis are not always found. The definitive diagnosis can usually be made with kidney biopsy. Patientes with TAC induced thrombotic microangiopathy usually promptly recover after treatment withdrawal or reduction in the dose of TAC and a short course of plasma therapy, but the risk of rejection increases. Switching from TAC to cyclosporine has also been tried with resolution of the heolysis but thrombotic microangiopathy has been noted with both and this condition may later recur. We present a 29-year-old man who received a kidney-pancreas transplant for end-stage diabetic nephropathy. After initial induction with basiliximab, the immunosuppression consisted of prednisone, tacrolimus and mycophenolate mofetil. Twenty four days posttransplantation his renal function declined with a peak creatine level of 2.35 mg/dl. Laboratory studies showed thrombocytopenia and features of intravascular hemolysis. TAC associated hemolytic uremic syndrome was suspected and drug was immediately stopped and converted to sirolimus. Also he was treated with plasma infusion. The allograft biopsy showed focal glomerular and arteriolar acute thrombosis without evidence of rejection. Our experience demostrate that switching from tacrolimus to sirolimus could be an adecuate strategy for patients who develop FK506-associated de novo thrombotic microangiopathy without increase risk of acute rejection (AU)</dc:description>
<dc:creator>Alférez, MJ</dc:creator>
<dc:creator>Cabello, M</dc:creator>
<dc:creator>González Molina, M</dc:creator>
<dc:creator>Gutiérrez de la Fuente, C</dc:creator>
<dc:creator>Navarro, A</dc:creator>
<dc:creator>Burgos, D</dc:creator>
<dc:creator>Sola, E</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El síndrome hemolítico urémico, de novo es la forma más severa de toxicidad aguda producida por los anticalcineurínicos. La retirada del fármaco puede resolver el cuadro, pero aumenta el riesgo de pérdida del injerto por rechazo agudo. En estos casos, la conversión a sirolimus puede ser la solución, ya que nos permite mantener una inmunosupresión eficaz en la prevención del rechazo agudo carente de toxicidad sobre las células endoteliales. Se presenta un paciente de 29 años trasplantado de riñón-páncreas, tratado con tacrolimus que desarrolla esta complicación en el postoperatorio y que se resuelve con la conversión a sirolimus y la administración de plasma fresco. En conclusión, la presencia de determinados datos clínicos y analíticos, en conjunto, nos permiten una orientación inicial para el diagnóstico diferencial entre ambas entidades (AU)</dc:description>
<dc:source>Nefrologia;24(supl.3): 3-6, 2004. graf</dc:source>
<dc:identifier>ibc-145759</dc:identifier>
<dc:title xml:lang="es">Síndrome hemolítico urémico de novo en el postoperatorio de un trasplante renopancreático</dc:title>
<dc:subject>^d29545</dc:subject>
<dc:subject>^d6615^s22067</dc:subject>
<dc:subject>^d7851</dc:subject>
<dc:subject>^d7861^s22027</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d33809</dc:subject>
<dc:subject>^d7344^s22020</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d22622^s22073</dc:subject>
<dc:subject>^d19331</dc:subject>
<dc:subject>^d920^s22073</dc:subject>
<dc:subject>^d3951^s22012</dc:subject>
<dc:subject>^d9365</dc:subject>
<dc:subject>^d3944^s22012</dc:subject>
<dc:subject>^d29497^s22027</dc:subject>
<dc:subject>^d6615^s22036</dc:subject>
<dc:subject>^d11622</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d30103^s22020</dc:subject>
<dc:subject>^d29475</dc:subject>
<dc:subject>^d4419</dc:subject>
<dc:subject>^d22926</dc:subject>
<dc:subject>^d3944^s22009</dc:subject>
<dc:subject>^d22886</dc:subject>
<dc:subject>^d6615^s22053</dc:subject>
<dc:subject>^d11383</dc:subject>
<dc:type>article</dc:type>
<dc:date>200400</dc:date>
</metadata>
</record>
</ibecs-document>
